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Abstract Atherosclerosis is an immunoinflammatory pro-
cess that involves complex interactions between the vessel
wall and blood components and is thought to be initiated by
endothelial dysfunction [1–3]. Extracellular nucleotides that
are released from a variety of arterial and blood cells [4]
can bind to P2 receptors and modulate proliferation and
migration of smooth muscle cells (SMC), which is known
to be involved in intimal hyperplasia that accompanies
atherosclerosis and postangioplasty restenosis [5]. In
addition, P2 receptors mediate many other functions,
including platelet aggregation, leukocyte adherence, and
arterial vasomotoricity. A direct pathological role of P2
receptors is reinforced by recent evidence showing that up-
regulation and activation of P2Y2 receptors in rabbit
arteries mediates intimal hyperplasia [6]. In addition, up-
regulation of functional P2Y receptors also has been
demonstrated in the basilar artery of the rat double-
hemorrhage model [7] and in coronary arteries of diabetic
dyslipidemic pigs [8]. It has been proposed that up-
regulation of P2Y receptors may be a potential diagnostic
indicator for the early stages of atherosclerosis [9].
Therefore, particular effort must be made to understand
the consequences of nucleotide release from cells in the
cardiovascular system and the subsequent effects of P2
nucleotide receptor activation in blood vessels, which may
reveal novel therapeutic strategies for atherosclerosis and
restenosis after angioplasty.
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Introduction
Atherosclerosis is a pathological phenomenon primarily
affecting the large conduit arteries, for example, the aorta
and coronary, carotid iliac, and femoral arteries. Develop-
ment of atherosclerotic lesions in arteries involves intimal
recruitment of smooth muscle cells (SMC) within the
blood-vessel wall and also infiltration of blood-derived
cells [1]. This process necessitates the proliferation and
migration of SMC from the underlying media and the
endothelial adhesion of leukocytes and their infiltration into
the subendothelium. A similar intimal accumulation of
SMC also takes place during the postangioplasty restenotic
process. Although the factors involved in intimal-cell
recruitment are not clearly identified, it is becoming evident
that endothelial dysfunction is a key factor in the
development of vascular disease. Experimental evidence
suggests that an intact endothelium plays a central role in
maintaining a low proliferative state of SMC under normal
conditions [10]. In arterial injury, endothelial cells, SMC,
and various blood cells can release chemotactic factors and
mitogens, including ATP and other nucleotides [4]. Acti-
vation of P2 nucleotide receptors has been shown to induce
not only the proliferation and migration of vascular SMC
but also apoptosis (programmed cell death), a process
involved in the evolution of atherosclerotic plaque [11]. In
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vasoconstriction of arteries that may be involved in the
vascular remodeling accompanying atherosclerosis and
postangioplasty restenosis [5]. A better understanding of
the causative agents and mechanisms of proliferation and
migration of vascular SMC as well as recruitment of
blood-derived cells by the endothelium could lead to
prevention, attenuation, or even reversal of intimal thick-
ening, which may dramatically reduce morbidity and
mortality from vascular diseases such as atherosclerosis
and restenosis after angioplasty. In this respect, a better
understanding of the physiological role of P2 receptors in
both normal and pathological blood vessels could poten-
tially lead to a breakthrough in the fight against vascular
disease.
P2 receptors in the cardiovascular system
Extracellular nucleotides bind to cell-surface receptors
known as P2 receptors, which are present in many tissues.
To date, these receptors have been classified into two main
families: the P2X receptors that are ligand-gated ion
channels comprised of homo- or hetero-oligomers [12],
and P2Y receptors that are seven-membrane-spanning
receptors coupled via G proteins (Gq/11 or Gi/o) to phos-
pholipase C (PLC) and/or adenylate cyclase [12–14]. In
turn, PLC activation generates inositol 1,4,5-triphosphate
(IP3), a mediator of Ca
2+ release from intracellular stores,
and diacylglycerol, an activator of protein kinase C (PKC)
whereas adenylate cyclase generates cyclic AMP, an
activator of protein kinase A (PKA). The cloning of seven
P2X (P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, P2X7) and
eight P2Y (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13,
P2Y14) receptor subtypes has made it possible to use
molecular and pharmacological approaches to study the
distribution and functional properties of specific P2
receptor subtypes at the tissue and cellular level.
P2 receptors in vascular cells
The normal arterial wall consists of three layers: intima,
media, and adventitia. The single layer of endothelial cells
facing the vessel lumen is a very important component of
the vascular wall in terms of releasing both vasodilators
such as nitric oxide (NO) and prostacyclin (PGI2), and
vasoconstrictors such as thromboxane A2 and endothelin.
The principal P2Y receptor subtypes that have been
functionally characterized in endothelial cells are P2Y1
and P2Y2, but mRNAs for P2Y4 and P2Y6 receptors have
also been detected [4]. Endothelium-dependent vasorelax-
ation has been attributed to the release of NO and PGI2
after binding of nucleotides to P2Y1 and P2Y2 receptors in
endothelial cells [15] whereas vasoconstrictor effects in
SMC result from the action of nucleotides on P2Y2 and
P2X receptors [16, 17]. In most blood vessels, P2Y1 re-
ceptors for ADP are present on the endothelium and
regulate vasodilatation by Ca
2+-dependent (PLC-mediated)
activation of NO synthase (NOS) and generation of
endothelial-dependent relaxing factor (EDRF) [4]. Endo-
thelial prostacyclin production is also stimulated by
P2Y1 and P2Y2 receptors, but this seems to play a minimal
role in vasodilatation, at least under physiological con-
ditions [18]. Recent studies have indicated that in the aorta
of P2Y2-null mice, the endothelium-dependent relaxation
by ATP and ATPγS was inhibited, demonstrating the role
of the P2Y2 receptors, but that a relaxation by UTP and
UDP was maintained, suggesting the additional involve-
ment of P2Y6 receptors [19]. The majority of cells in intact
blood vessels are SMC, which occupy most of the media
and are involved in vessel vasoconstriction and vaso-
relaxation. P2Y2Rs in SMC mediate the induction of
immediate-early and delayed-early cell-cycle-dependent
genes, consistent with a role for P2Y2Rs in vascular
proliferation of SMC [20, 21]. A recent study demonstrated
that P2Y2 is the predominant functional receptor that
responds to ATP and UTP in rat aortic SMC [22]. In
human cerebral arteries, P2Y6 seems to be the predominant
subtype and induces vasoconstriction when activated by
UDP/UTP [23, 24]. This is consistent with findings from
rat pulmonary and mesenteric arteries [25, 26]. In addition,
a recent study on P2X1 knock-out mice further supports the
prominent contractile effect of the P2Y6 subtype in
mesenteric arterial trees [27]. Taken together, it seems that
the principal receptor mediating UTP/UDP-induced con-
tractile responses in blood vessels might be the P2Y6
subtype. Other studies have reported the presence of both
P2Y4 and P2Y6 receptors in rat aortic SMC [21, 28, 29].
P2Y1 receptors are expressed in SMC of a number of blood
vessel types and, like their endothelial cell counterparts,
mediate vasodilatation most likely through the activation of
K
+ channels [18]. The presence of several P2X receptor
subtypes also has been reported in human saphenous vein
SMC, including P2X1, P2X2, P2X4, and P2X7 receptors
[30]. The outermost layer of the blood vessel consists of
connective tissue and fibroblasts, which have not been
appreciated in the regulation of vascular tone. A recent
study showed that fibroblasts can migrate into the
neointima, suggesting their possible involvement in the
development of vascular diseases such as atherosclerosis
and restenosis after angioplasty [31]. Since human and rat
fibroblasts are known to express P2Y1, P2Y2, P2Y4, P2Y6,
P2X3,P 2 X 4, and P2X7 receptors [32], further investigation
is needed to establish the role of fibroblast P2 receptors
in either physiological or pathophysiological conditions.
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G-protein-coupled P2Y receptors the activation of which
leads to intracellular calcium mobilization have been
observed in neutrophils [4, 33, 34], and turkey erythrocytes
express both P2Y1 and P2X7 receptors [35, 36]. ATP and
UTP act as secretagogues by binding to P2Y2Rs to enhance
exocytosis of primary granules in neutrophils [37]. In
macrophages, ATP activates a P2X7 receptor that differs
from other ligand-gated ion-channel P2X receptors by its
ability to generate plasma membrane pores when activated
[38]. Human T lymphocytes also have been shown to
express P2X7 receptors [39]. Human monocytes and
macrophages coexpress P2X1, P2X4, and P2X7 receptors
whereas granulocytes only express P2X7 receptors [40].
P2Y1, P2Y2, and P2Y6 receptors also are expressed in
monocytes, B lymphocytes, and polymorphonuclear gran-
ulocytes [41]. Human platelets express P2Y1, P2Y12, and
P2X1 receptors [42–44]. Thus, the diversity of P2-receptor
expression in blood cells, as well as endothelial cells, SMC
and fibroblasts, suggests that this receptor superfamily
plays a significant role in the regulation of cardiovascular
functions.
P2 receptors regulate nucleotide-induced vascular
smooth muscle cell proliferation
Proliferation of SMC is a hallmark of vascular diseases
such as atherosclerosis and restenosis following angioplas-
ty. ATP and other nucleotides are released by aggregating
platelets and damaged vascular cells, such as endothelial
cells and SMC in pathological or stress conditions [45].
Extracellular nucleotides can act via P2X and P2Y
receptors to induce acute responses such as regulation of
vascular tone [46]. However, it is generally believed that
the ionotropic P2X receptors do not mediate the chronic
responses of nucleotides, such as cell proliferation. The
mitogenic effect of extracellular nucleotides on vascular
SMC (VSMC) has been known for years [47]. However, a
potent antiproliferative effect of UTP on VSMC also has
been reported in human arterial and venous SMC [48]. In
either case, the P2 receptor subtype(s) responsible for these
effects on the proliferation of VSMC has not been
determined. Earlier studies have shown that ATP or UTP
increases DNA and protein synthesis in subcultured rat
aortic VSMC [49, 50]. In the same cell-culture model,
however, Malam-Souley et al. [51] were unable to detect
increases in DNA synthesis after ATP/UTP stimulation
although ATP or UTP up-regulated the expression of
mRNA to several cell-cycle, progression-related genes.
Because P2X receptor agonists were essentially inactive,
it was concluded that a P2U-like receptor (now termed
P2Y2) was responsible for the mitogenic effects of ATP/
UTP. However, the role of a P2Y4 receptor cannot be
excluded because the nucleotide agonist profile between rat
P2Y2 and P2Y4 receptors is essentially indistinguishable
[52]. Indeed, Harper et al. [53] suggested that the P2Y4
receptor mediated ATP/UTP-induced proliferation of rat
aortic VSMC. Recent studies indicated that ATP, UTP, or
ITP, three agonists of the cloned porcine P2Y2 receptor,
increased DNA and protein synthesis and cell number in
coronary artery SMC [54]. Indeed, treatment of pig
coronary artery SMC with UTP, ATP, or ITP caused a
concentration-dependent increase in DNA and protein
synthesis and cell number whereas UDP only caused a
small increase in protein synthesis. Intriguingly, ATP was
much more potent and efficacious than UTP, ITP, and UDP
in increasing DNA synthesis and expression of PCNA, a
protein marker of cell proliferation, suggesting that another
receptor may contribute to the proliferative response [54].
In vivo experiments have shown that intimal thickening of
collared rabbit carotid arteries was greatly enhanced by in
situ UTP application and was closely associated with
osteopontin expression in medial SMC [6]. Osteopontin is
chemotactic for SMC and is associated with arterial SMC
proliferation [55]. Moreover, both UTP and ATP increased
osteopontin expression in cultured SMC whereas ADP,
UDP, and 2-MeSATP were ineffective, which suggests a
role for the P2Y2R in which ATP and UTP are equipotent.
Direct evidence for involvement of the P2Y2Rw a s
provided by inhibition of UTP-induced osteopontin expres-
sion in cultured SMC by P2Y2 antisense oligonucleotides
[6]. P2Y6 receptors also have been shown to mediate
proliferation of SMC in rat aorta [56].
Role of P2 receptors in the migration of vascular SMC
Recent studies indicate that the extracellular nucleotides
ATP, ADP, UTP, and UDP serve as directional cues for
migration of rat aortic SMC [57]. At identical concen-
trations, the most powerful migratory response induced by
these nucleotides was elicited by UTP. Nucleotide-induced
migration of SMC is the consequence of both chemotaxis
and chemokinesis and may result either from activation of
one particular P2 nucleotide receptor subtype or of several
P2 receptor subtypes. The ability of UTP at submicromolar
levels to stimulate migration of SMC supports the hypoth-
esis that this response could have physiological consequen-
ces and is essentially mediated by P2Y2 receptor activation
without excluding participation of other P2Y receptor
subtypes. The difference in the capacity of UTP and ATP
to elicit migration of SMC could be due to inhibition of
nucleotide-induced cell migration by adenosine generated
from ATP catabolism by cell-surface ectonucleotidases.
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migration of SMC when ATP was prevented from degra-
dation by addition of the ectonucleotidase inhibitor α,β-
methylene-ATP [57]. Several P2Y receptor subtypes could
be involved in nucleotide-induced migration of SMC. It has
been shown in rat aortic SMC that the P2Y2 receptor is the
predominant P2Y receptor subtype [28, 58] whereas lower
levels of P2Y4 and P2Y1 receptor mRNA were detected
[58]. The very low level of P2Y1 receptor mRNA
expression was consistent with the absence of ADP-
induced migration of cultured rat aortic SMC, demonstrat-
ing that P2Y1 is not involved in this process [58]. In
addition, the same study showed that a commercially
available solution of hexokinase-treated UDP (UTP-free)
induced cell migration equally as well as untreated UDP,
thereby demonstrating that UDP is chemotactic for aortic
SMC by activation of the P2Y6 receptor. Conversely,
migration of rat aortic SMC induced by UTP occurred
even when UTP degradation by nucleoside diphosphate
kinase was inhibited, demonstrating the involvement of
P2Y2 and/or P2Y4 receptor(s) [58].
The increased migration of SMC in response to extracel-
lular nucleotides could be related to increases in extracellular
matrix (ECM) protein expression. Indeed, previous studies
have shown that UTP induces osteopontin expression in rat
and rabbit aortic SMC [6, 51]. Increased expression of
osteopontin, an RGD-containing ECM protein, is associat-
ed with the activation of rat arterial SMC in vitro and in
vivo [57]. The increase in osteopontin expression plays a
key role in UTP-induced migration of rat aortic SMC since
a monoclonal antibody against osteopontin fully abolished
UTP-induced migration [57] whereas an antibody against
vitronectin, another ECM protein also involved in migra-
tion of human SMC [59], had no effect on the migration of
rat aortic SMC [57]. UTP induces increases in osteopontin
mRNA expression by increasing both osteopontin mRNA
stabilization and osteopontin promoter activity [60]. Recent
studies have shown that activation of an AP-1 binding site
located 76 bp upstream of the transcription start in the rat
osteopontin promoter is involved in UTP-induced osteo-
pontin expression. Using a luciferase promoter deletion
assay, Renault et al. [61] identified a new region of the rat
osteopontin promoter (−1837 to −1757) that is responsive
to UTP. This region contains an NFB site located at −1800
and an Ebox located at −1768. Supershift electrophoretic
mobility shift and chromatin immunoprecipitation assays
identified NFB and USF-1/USF-2 as DNA-binding proteins
induced by UTP. Using dominant negative mutants of IB
kinase and USF transcription factors, it was confirmed that
NFB and USF-1/USF-2 are involved in the UTP-induced
expression of osteopontin.
This ability of nucleotides to act as chemoattractants for
rat arterial SMC in a concentration range potentially found
in pathological vessels [62] and the findings of previous
studies demonstrating the mitogenic activity of extracellular
nucleotides for these cells suggest that nucleotides released
from mechanically stretched vascular or damaged cells
during the angioplasty process may participate in arterial-
wall remodeling.
Role of P2 receptors in nucleotide-induced
vascular inflammation
In addition to their mitogenic effects, extracellular nucleo-
tides may also cause cell recruitment by inducing lympho-
cyte and macrophage adhesion to human pulmonary artery
endothelial cells, as demonstrated in vitro [63]. Nucleotides
can also modulate rat aortic SMC adhesion and migration
by increasing the expression of osteopontin [51, 57], a
protein involved in both processes. Moreover, extracellular
nucleotides may play a role in intra-arterial attraction of
monocytes by inducing an increased expression of mono-
cyte-chemoattractant protein-1 by arterial SMC [21].
Stimulation of P2 receptors is coupled to the release of
the proinflammatory cytokines IL-1β, IL-1α, IL-8, and
TNF-α [4] that are of obvious relevance to inflammation in
atherosclerosis. Activation of P2X7 receptors on mono-
cytes/macrophages enhances release of proinflammatory
cytokines that modulate NO production and expression of
inducible NO synthase (iNOS) [64], mediators of immune
cell activation that is an early step in atherosclerotic lesion
development.
Monocyte recruitment into the vessel wall is a complex
process that includes cell rolling, firm attachment, and
directed migration. It is now becoming evident that ad-
hesion molecules such as VCAM-1 play an important role
in leukocyte adherence to vascular endothelial cells [65,
66]. VCAM-1 expression is induced or up-regulated by
proinflammatory cytokines such as TNF-α and IL-1β in
cellular components of the arterial wall, including endothe-
lial cells, SMC, and fibroblasts [67–69]. ATP and UTP have
been shown to induce cell–cell adhesion in a human
monocyte/macrophage lineage and neutrophil adherence to
human endothelial cell monolayers [63, 70].
Recent studies have shown that local UTP delivery via
an osmotic pump to collared rabbit carotid arteries induced
intimal accumulation of macrophages, similar to oxidized
low-density lipoprotein (LDL), a response that was medi-
ated by activation of P2Y2 receptors [6]. Leukocyte
migration depends on the activities of adhesion proteins
(e.g., selectins and integrins) on leukocytes and vascular
endothelial cells. We demonstrated that activation of
P2Y2 receptors in endothelial cells causes expression of
VCAM-1 that mediates adherence of monocytes to vascular
endothelium [71], leading to their penetration into the
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with atherosclerosis.
Recent studies revealed that a Src homology-3 (SH3)-
binding domain in the C-terminal tail of the P2Y2 receptor
promotes nucleotide-induced association of Src with the
P2Y2 receptor, leading to transactivation of growth factor
receptors, such as the EGF and VEGF receptors, and nu-
cleotide-induced up-regulation of VCAM-1 [72, 73]. Since
leukocyte infiltration and migration are key processes
involved in atherosclerosis, these findings suggest that
P2Y2 receptors represent a novel target for reducing arterial
inflammation associated with cardiovascular disease.
P2 receptors in vascular apoptosis
Apoptosis has been reported to occur in various vascular
diseases, such as atherosclerosis, restenosis, and hyperten-
sion [74, 75]. The major cell types undergoing apoptosis in
human atherosclerotic lesions are arterial SMC [11, 76–78]
and macrophages [79]. In restenosis following balloon
angioplasty, there is a peak in the proliferation and
apoptosis of rat vascular SMC 14 days postangioplasty
[76]. Furthermore, apoptosis of arterial SMC has been
described in animal models of intimal thickenings [80] and
probably takes part in the normal process involved in the
control of hyperplasia. In contrast, apoptosis of SMC in
advanced human atherosclerotic plaques may destabilize
the fibrous lesion to promote plaque rupture and its clinical
consequences.
As a mediator of cell-to-cell communication, ATP can
trigger a variety of biological responses after being rapidly
released in large amounts from various sources, including
activated platelets, endothelial cells, nerve terminals,
antigen-stimulated T cells, and other cell types following
hypoxia, stress, and tissue damage. For example, in human
umbilical cord vein endothelial cells (HUVEC), substantial
release of ATP (and UTP) is induced by shear stress [81],
which may lead to alterations in the balance between
proliferation and apoptosis regulated by P1 adenosine and
P2 (particularly P2X7) nucleotide receptors [82]. P2X7 and
P1 receptors have been previously linked to apoptosis in
other cell types, including immune cells, astrocytes, and
thymocytes [83–85]. The P2X7R also has been shown to
mediate ATP-induced cell death in human embryonic
kidney cells [86], human cervical epithelial cells [87], and
primary rat cortical neurons [88]. In human arterial SMC,
adenosine-induced apoptosis is essentially mediated via the
A2b-adenosine receptor subtype and involves a cAMP-
dependent pathway [89].
As an important constituent of atherosclerotic plaques,
fibroblasts share several features with SMC. In human
fibroblasts, P2X7 was identified as the main nucleotide
receptor involved in the high glucose concentration-
dependent responses modulated by ATP, including
morphological changes, enhanced apoptosis, caspase-3
activation, and IL-6 release [90]. In the immune system,
ATP also plays important roles through nucleotide receptors
in leukocyte functions. P2X7-receptor-mediated apoptosis
has been demonstrated in various types of leukocytes,
including a lymphocytic cell line, murine thymocytes, mu-
rine peritoneal macrophages, human macrophages, mesan-
gial cells, dendritic cells, and microglial cells [83, 91–96].
Extracellular ATP acting via the P2X7 receptor activates the
transcription factor NF-κB by selectively targeting NF-κB
p65 (Rel A) in the N9 mouse microglial cell line [97]. It
also has been reported that the P2X7 receptor modulates
macrophage production of TNF-α, IL-1β and NO follow-
ing LPS exposure [98], consistent with a role for the P2X7
receptor in inflammation. In HUVEC, TNF-α markedly
increases apoptotic cell death via the activation of caspase-3
[74]. Recent reports indicate that ATP/ADP activate NF-κB
and induce apoptosis, probably through P2X7 receptors in
porcine aortic endothelial cells [99]. These studies have
provided compelling evidence suggesting a role for P2- and
P1-receptor-mediated apoptosis in vascular diseases; how-
ever, further studies are needed to determine the precise
pathways involved and to accumulate direct evidence that
these pathways contribute significantly to the development
of atherosclerosis, hypertension, and restenosis.
Modulation of P2 receptors in vascular injury
Experimental arterial intimal hyperplasia can be induced by
balloon angioplasty or by perivascular placement of a
silicone collar around an artery. An influx of leukocytes
precedes migration and proliferation of vascular SMC into
the intima in both these models [100]. In normal adult rat
aorta, P2Y2 mRNA was found in endothelial cell lining
while a sustained expression of P2Y2 mRNA was detected
in a few medial SMC [20]. In contrast, P2Y2 mRNA was
detected in all medial SMC of rat fetal aortas and in most
aortic SMC of intimal lesions after balloon angioplasty,
with an overexpression in cells lining the lumen both 1 and
3 weeks after injury.
In the collar model, neointimal formation appears to be
triphasic [100]. The first phase is characterized by vascular
infiltration of leukocytes beginning 2 h after collar
placement around a rabbit carotid artery. The second phase
begins within 12 h of collar placement and is characterized
by medial replication of SMC. The third phase is
characterized by the appearance, beginning at day 3 after
collar placement, of subendothelial SMC. In situ hybrid-
ization with sham-operated rabbit carotid arteries indicated
that P2Y2 mRNA expression was localized to CD31-
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High levels of P2Y2 mRNA were detected in medial SMC
3 days after collar placement, before appearance of neo-
intima. At day 14, all intimal and medial SMC were P2Y2
positive. Fura-2 digital imaging of single SMC, used to
measure changes in myoplasmic calcium concentration in
response to P2Y receptor agonists, confirmed an increase in
P2Y2 receptor activity. However, the same study showed
that P2Y4 mRNA was equivalently expressed in sham-
operated and collared arteries or cultured rabbit carotid
SMC whereas P2Y6 mRNA was not detected in carotid
arteries or cultured SMC. In a more recent study, it was
shown that P2Y2 receptor up-regulation occurs in stented
porcine coronary artery, a clinically relevant model of
arterial injury [54]. P2Y2 receptor mRNA levels were
significantly increased in coronary SMC dispersed from
stented segments of coronary arteries 3 weeks after stent
angioplasty compared with SMC from unstented segments.
There was no significant difference observed in levels of
P2Y6 mRNA in the stented and unstented artery segments
whereas P2Y4 receptor mRNA was undetectable.
Up-regulation of functional P2Y receptors also occurs in
the basilar artery of the rat double-hemorrhage model [7], in
the coronary artery of diabetic dyslipidemic pigs [8], and
in human atherosclerotic lesions (Seye and Desgranges,
unpublished data). It has been proposed that up-regulation
of P2Y receptors could be a potential diagnostic indicator
for the early stages of atherosclerosis [9]. Interestingly, a
more recent study showed that high shear stress associated
with vascular diseases can selectively up-regulate P2Y2 and
P2Y6 receptors in perfused arterial SMC [101]. P2X1 and
P2X4 receptors have been shown to be up-regulated in
rabbit intimal thickenings [102]. Taken together, these
findings strongly suggest that at least some P2 receptor
subtypes (most notably P2Y2) are implicated in the
development of vascular disease.
Pathophysiological significance of P2 receptor
modulation in vascular injury
Migrating and proliferating SMC in the arterial media,
together with infiltrating macrophages and T lymphocytes,
are the main cell types that comprise atherosclerotic and
restenotic lesions [1]. In the early stages of intimal
hyperplasia, SMC are modified from a differentiated,
contractile phenotype to an immature, synthetic phenotype,
and this enables them to migrate into the intima, proliferate,
and secrete extracellular matrix components. In many
respects, this shift in phenotype is a reversal of the normal
differentiation pattern of vascular SMC during fetal and
early postnatal life [103, 104]. However, there is still a lack
of knowledge concerning the phenotypic regulation of
SMC during vasculogenesis and vascular disease. A high
level of P2 receptor expression could be related to the
altered phenotype of SMC in intimal thickenings. Partially
dedifferentiated SMC are found in rat arterial intimal
lesions after balloon angioplasty [105, 106], and their
phenotype has been compared with that of newborn rat
aortic SMC [107]. Interestingly, it has been reported that
medial SMC of rat embryonic aorta also exhibit high P2Y2
expression similar to intimal thickenings [20]. Others
studies have shown that P2Y1 and P2Y2 receptor transcripts
are strongly up-regulated with phenotypic changes in rat
SMC whereas P2X1 mRNA is completely down-regulated
and P2Y4 and P2Y6 mRNA levels are unchanged [28, 58].
Taken together, these and other results suggest that P2Y2
receptor expression is up-regulated in the entire cell
population of intimal thickenings and is closely associated
with a poorly differentiated phenotype of SMC. The
dramatic increase in P2Y2 mRNA expression observed in
balloon angioplasty-induced intimal lesions would suggest
increased activity of extracellular nucleotides with conse-
quent enhancement of cell proliferation and vasoreactivity.
Indeed, extracellular nucleotides, particularly ATP and
UTP, have been shown to induce cell-cycle progression
and proliferation of cultured arterial SMC [21, 49, 50, 51]
and vasoconstriction in the absence of endothelial cells [17,
108, 109]. Since both neointimal hyperplasia and vasocon-
strictive remodeling have been found to be involved in
postangioplasty restenosis [1, 5, 107, 110], these findings
suggest that extracellular nucleotides may play a significant
role in this process, at least as long as functional endothelial
cells, which regulate intimal thickening [111, 112] and
nucleotide-induced vasorelaxation [113, 114], are not
regenerated.
Increased P2Y2 receptor expression in the neointima
may by itself be sufficient to enhance local effects of
extracellular nucleotides on proliferation of SMC. Although
expression of other P2 receptors has been described in
arterial SMC [21, 29, 115], the P2Y2 receptor seems to be
more specifically involved in the response of SMC to ATP
and UTP [116], particularly in potentiation of proliferation
[21, 50]. Effects of extracellular nucleotides are not only
dependent on the nature and number of P2 receptors present
on target cells but also on local concentrations of nucleotide
agonists. Although in vivo concentrations of extracellular
nucleotides are difficult to measure, various in vitro
experiments suggest that extracellular nucleotides are
released from blood and vascular cells exposed to various
physicochemical conditions, e.g., stress, hypoxia, and other
factors [117–119] associated with the angioplasty process.
P2Y2 receptors in SMC are involved in nucleotide-
induced constriction of normal arteries [17, 108, 109].
Long-lasting alterations in vasomotricity after endothelial-
cell denudation, resulting in increased sensitivity to
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strated [113, 114]. It appears that, like other receptors for
vasoconstrictive factors such as angiotensin II [120],
endothelin [121], and PDGF [122], which are overex-
pressed in neointima, P2Y2 receptors may play an impor-
tant role in controlling vasoactive properties of pathological
arteries, particularly in chronic constriction at the lesion site
that is postulated to be one of the processes leading to
postangioplasty restenosis [5, 110].
Conclusion
P2 receptor subtypes, including P2Y2, P2X1 and P2X4,
appear to play a role in responses to endothelial injury that
are thought to be key events in the initiation of atheroscle-
rosis and restenosis after angioplasty. P2Y2R up-regulation
and activation in endothelial cells and SMC promote
leukocyte transmigration and intimal thickening in arteries
of animal models of vascular injury, suggesting a possible
regulatory role for this receptor in mechanisms leading to
neointimal hyperplasia after angioplasty. Although there are
no selective P2Y2 receptor antagonists yet available, recent
progress in small interfering RNA (siRNA) technology has
made it possible to design small RNA interference
molecules that can selectively inhibit P2 receptor subtype
expression. Such molecules can be efficiently delivered into
the vessel wall using adenoviral vectors. In addition, P2
receptor transgenic mice (i.e., mice in which the relevant
receptor subtype has been deleted or overexpressed) will be
valuable tools to substantiate the role that nucleotides and
P2 receptors play in the etiology of cardiovascular disease.
Further delineation of signaling pathways involved in these
P2 receptor-mediated processes may help limit or prevent
vascular diseases such as atherosclerosis and restenosis
after angioplasty.
References
1. Ross R (1993) The pathogenesis of atherosclerosis: a perspective
for the 1990s. Nature 362(6423):801–809
2. Fuster V, Badimon L, Badimon JJ, Chesebro JH (1992) The
pathogenesis of coronary artery disease and the acute coronary
syndromes (1). N Engl J Med 326(4):242–250
3. Davies MJ, Woolf N (1993) Atherosclerosis: what is it and why
does it occur? Br Heart J 69(1):S3–S11
4. Di Virgilio F, Solini A (2002) P2 receptors: new potential players
in atherosclerosis. Br J Pharmacol 135(4):831–842
5. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF,
Chisolm GM (1995) Restenosis after experimental angioplasty:
intimal, medial, and adventitial changes associated with con-
strictive remodeling. Circ Res 76(6):996–1002
6. Seye CI, Kong Q, Erb L, Garrad RC, Krugh B, Wang M, Turner
JT, Sturek M, Gonzalez FA, Weisman GA (2002) Functional
P2Y2 nucleotide receptors mediate uridine 5’-triphosphate-
induced intimal hyperplasia in collared rabbit carotid arteries.
Circulation 106(21):2720–2726
7. Carpenter RC, Miao L, Miyagi Y, Bengten E, Zhang JH (2001)
Thesis Altered expression of P2 receptor mRNAs in the basilar
artery in a rat double hemorrhage model. Stroke 32(2):516–522
8. Hill BJ, Wamhoff BR, Sturek M (2001) Functional nucleotide
receptor expression and sarcoplasmic reticulum morphology in
dedifferentiated porcine coronary smooth muscle cells. J Vasc
Res 38(5):432–443
9. Elmaleh DR, Narula J, Babich JW, Petrov A, Fischman AJ,
Khaw BA, Rapaport E, Zamecnik PC (1998) Rapid noninvasive
detection of experimental atherosclerotic lesions with novel
99mTc-labeled diadenosine tetraphosphates. Proc Natl Acad Sci
USA 95(2):691–695
10. Casscells W (1992) Migration of smooth muscle and endothelial
cells. Critical events in restenosis. Circulation 86(3):723–729
11. Isner JM, Kearney M, Bortman S, Passeri J (1995) Apoptosis
in human atherosclerosis and restenosis. Circulation 91(11):
2703–2711
12. North RA, Surprenant A (2000) Pharmacology of cloned P2X
receptors. Ann Rev Pharmacol Toxicol 40:563–580
13. Cooper DM, Rodbell M (1979) ADP is a potent inhibitor of
human platelet plasma membrane adenylate cyclase. Nature 282
(5738):517–518
14. Communi D, Gonzales NS, Detheux M, Brezillon S, Lannoy V,
Parmentier M, Boeynaems J-M (2001) Identification of a novel
human ADP receptor coupled to G1. J Biol Chem 276(44):
41479–41485
15. Ralevic V, Burnstock G (1991) Roles of P2-receptors in the
cardiovascular system. Circulation 84(1):1–14
16. Saiag B, Milon D, Shacoori V, Allain H, Rault B, van den
Driessche J (1992) Newly evidenced pyrimidinoceptors and the
P2X receptors are present on the vascular smooth muscle and
respectively mediate the UTP- and ATP-induced contractions of
the dog maxillary internal vein. Res Commun Chem Pathol
Pharmacol 76(1):89–94
17. von Kügelgen I, Starke K (1990) Evidence for two separate
vasoconstriction-mediating nucleotide receptors, both distinct
from the P2X-receptor, in rabbit basilar artery: a receptor for
pyrimidine nucleotides and a receptor for purine nucleotides.
Naunyn-Schmiedeberg’s Arch Pharmacol 341(6):538–546
18. Ralevic V, Burnstock G (1998) Receptors for purines and
pyrimidine. Pharmacol Rev 50(3):413–492
19. Guns PJ, Van Assche T, Fransen P, Robaye B, Boeynaems JM,
Bult H (2006) Endothelium-dependent relaxation evoked by ATP
and UTP in the aorta of P2Y2-deficient mice. Br J Pharmacol
147(5):569–574
20. Seye CI, Gadeau AP, Daret D, Dupuch F, Alzieu P, Capron L,
Desgranges C (1997) Overexpression of P2Y2 receptor in intimal
lesions of the rat aorta. Arterioscler Thromb Vasc Biol 17(12):
3602–3610
21. Malam-Souley R, Seye CI, Gadeau AP, Loirand G, Pillois X,
Campan M, Pacaud P, Desgranges, C (1996) Nucleotide receptor
P2u partially mediates ATP-induced cell cycle progression of
aortic smooth muscle cells. J Cell Physiol 166(1):57–65
22. Kumari R, Goh G, Ng LL, Boarder MR (2003) ATP and UTP
responses of cultured rat aortic smooth muscle cells revisited:
dominance of P2Y2 receptors. Br J Pharmacol 140(7):
1169–1176
23. Malmsjo M, Hou M, Pendergast W, Erlinge D, Edvinsson L
(2003) The stable pyrimidines UDPβS and UTPγS discriminate
between contractile cerebrovascular P2 receptors. Eur J
Pharmacol 458(3):305–311
24. Malmsjo M, Hou M, Pendergast W, Erlinge D, Edvinsson L
(2003) Potent P2Y6 receptor mediated contractions in human
cerebral arteries. BMC Pharmacol 3:4
Purinergic Signalling (2006) 2:471–480 47725. Hartley SA, Kato K, Salter KJ, Kozlowski RZ (1998) Functional
evidence for a novel suramin-insensitive pyrimidine receptor in
rat small pulmonary arteries. Circ Res 83(9):940–946
26. Malmsjo M, Adner M, Harden TK, Pendergast W, Edvinsson L,
Erlinge D (2000) The stable pyrimidines UDPβS and UTPγS
discriminate between the P2 receptors that mediate vascular
contraction and relaxation of the rat mesenteric artery. Br J
Pharmacol 131(1):51–56
27. Vial C, Evans RJ (2002) P2X1 receptor-deficient mice establish
the native P2X receptor and a P2Y6-like receptor in arteries. Mol
Pharmacol 62(6):1438–1445
28. Erlinge D, Hou M, Webb TE, Barnard EA and Moller S (1998)
Phenotype changes of the vascular smooth muscle cell regulate
P2 receptor expression as measured by quantitative RT-PCR.
Biochem Biophys Res Commun 248(3):864–870
29. Chang K, Hanaoka K, Kumada M, Takuwa Y (1995) Molecular
cloning and functional analysis of a novel P2 nucleotide receptor.
J Biol Chem 270(44):26152–26158
30. Cario-Toumaniantz C, Loirand G, Ladoux A, and Pacaud P
(1998) P2X7 receptor activation-induced contraction and lysis in
human saphenous vein smooth muscle. Circ Res 83(2):196–203
31. Zalewski A, Shi Y, Johnson AG (2002) Diverse origin of intimal
cells: smooth muscle cells, myofibroblasts, fibroblasts, and
beyond? Circ Res 91(8):652–655
32. von Kugelgen I, Wetter A (2000) Molecular pharmacology of
P2Y receptors. Naunyn Schmiedeberg’s Arch Pharmacol 362(4–
5):310–323
33. Kuhns DB, Wright DG, Nath J, Kaplan SS, Basford RE (1988)
ATP induces transient elevations of [Ca
2+]i in human neutrophils
and primes these cells for enhanced O2
− generation. Lab Invest
58(4):448–453
34. Cowen DS, Lazarus HM, Shurin SB, Stoll SE, Dubyak GR
(1989) Extracellular adenosine triphosphate activates calcium
mobilization in human phagocytic leukocytes and neutrophil/
monocyte progenitor cells. J Clin Invest 83(5):1651–1660
35. Parker JC, Snow RL (1972) Influence of external ATP on
permeability and metabolism of dog red blood cells. Am J
Physiol 223(4):888–893
36. Boyer JL, Downes CP, Harden TK (1989) Kinetics of activation
of phospholipase C by P2 purinergic agonists and guanine
nucleotides. J Biol Chem 264(2):884–890
37. Cockcroft S, Stutchfield J (1989) ATP stimulates secretion in
human neutrophils and HL60 cells via a pertussis toxin-sensitive
guanine nucleotide-binding protein coupled to phospholipase C.
FEBS Lett 245(1–2):25–29
38. Steinberg TH, Newman AS, Swanson JA, Silverstein, SC (1987)
ATP
4− permeabilizes the plasma membrane of mouse macro-
phages to fluorescent dyes. J Biol Chem 262(18):8884–8888
39. Baricordi OR, Ferrari D, Melchiorri L, Chiozzi P, Hanau S,
Chiari E, Rubini M, Di Virgilio F (1996) An ATP-activated
channel is involved in mitogenic stimulation of human T
lymphocytes. Blood 87(2):682–690
40. Suh BC, Kim JS, Namgung U, Ha H, Kim KT (2001) P2X7
nucleotide receptor mediation of membrane pore formation and
superoxide generation in human promyelocytes and neutrophils.
J Immunol 166(11):6754–6763
41. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, Morelli
A, Torboli M, Bolognesi G, Baricordi OR (2001) Nucleotide
receptors: an emerging family of regulatory molecules in blood
cells. Blood 97(3):587–600
42. Sun B, Li J, Okahara K, Kambayashi J (1998) P2X1 receptor in
human platelets. J Biol Chem 273(19):11544–11547
43. Leon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C
(1997) The P2Y1 receptor is an ADP receptor antagonized by
ATP and expressed in platelets and megakarioblastic cells. FEBS
Lett 403(1):26–30
44. Hollopeter G, Jantzen H-M, Vincent D, Li G, England L,
Ramakrishnan V, Yang R-B, Nurden P, Nurden A, Julius D,
Conley PB (2001) Identification of the platelet ADP receptor
targeted by antithrombotic drugs. Nature 409(6817):202–207
45. Hamada K, Takuwa N, Yokoyama K, Takuwa Y (1998) Stretch
activates Jun N-terminal kinase/stress-activated protein kinase in
vascular smooth muscle cells through mechanisms involving
autocrine ATP stimulation of receptors. J Biol Chem 273
(11):6334–6340
46. Dubyak GR, El-Moatassim C (1993) Signal transduction via P2-
purinergic receptors for extracellular ATP and other nucleotides.
Am J Physiol 265(3 Pt 1):C577–C606
47. Wang DJ, Huang NN, Heppel LA (1992) Extracellular ATP and
ADP stimulate proliferation of porcine aortic smooth muscle
cells. J Cell Physiol 153(2):221–233
48. White PJ, Kumari R, Porter KE, London NJ, Ng LL, Boarder
MR (2000) Antiproliferative effect of UTP on human arterial and
venous smooth muscle cells. Am J Physiol Heart Circ Physiol
279(6):H2735–H2742.
49. Erlinge D, Yoo H, Edvinsson L, Reis DJ, Wahlestedt C (1993)
Mitogenic effects of ATP on vascular smooth muscle cells vs.
other growth factors and sympathetic cotransmitters. Am J
Physiol 265(4 Pt 2):H1089–H1097
50. Erlinge D, You J, Wahlestedt C, Edvinsson L (1995) Character-
isation of an ATP receptor mediating mitogenesis in vascular
smooth muscle cells. Eur J Pharmacol 289:135–149
51. Malam-Souley R, Campan M, Gadeau AP, Desgranges C (1993)
Exogenous ATP induces a limited cell cycle progression of
arterial smooth muscle cells. Am J Physiol 264(4 Pt 1):C783–
C788
52. Wildman SS, Unwin RJ, King BF (2003) Extended pharmaco-
logical profiles of rat P2Y2 and rat P2Y4 receptors and their
sensitivity to extracellular H
+ and Zn
2+ ions. r J Pharmacol 40
(7):1177–1186
53. Harper S, Webb TE, Charlton SJ, Ng LL, Boarder MR (1998)
Evidence that P2Y4 nucleotide receptors are involved in the
regulation of rat aortic smooth muscle cells by UTP and ATP. Br
J Pharmacol 124(4):703–710
54. Shen J, Seye CI, Wang M, Weisman GA, Wilden PA, Sturek M
(2004) Cloning, up-regulation, and mitogenic role of porcine
P2Y2 receptor in coronary artery smooth muscle cells. Mol
Pharmacol 66(5):1265–1274
55. Gadeau AP, Campan M, Millet D, Candresse T, Desgranges C
(1993) Osteopontin overexpression is associated with arterial
smooth muscle cell proliferation in vitro. Arterioscler Thromb 13
(1):120–125
56. Hou M, Harden TK, Kuhn CM, Baldetorp B, Lazarowski E,
Pendergast W, Moller S, Edvinsson L, Erlinge D (2002) UDP
acts as a growth factor for vascular smooth muscle cells by
activation of P2Y6 receptors. Am J Physiol Heart Circ Physiol
282(2):H784–H792
57. Chaulet H, Desgranges C, Renault MA, Dupuch F, Ezan G,
Peiretti F, Loirand G, Pacaud P, Gadeau AP (2001) Extracellular
nucleotides induce arterial smooth muscle cell migration via
osteopontin. Circ Res 89(9):772–778
58. Pillois X, Chaulet H, Belloc I, Dupuch F, Desgranges C,
Gadeau AP (2002) Nucleotide receptors involved in UTP-
induced rat arterial smooth muscle cell migration. Circ Res 90
(6):678–681
59. Dufourcq P, Louis H, Moreau C, Daret D, Boisseau MR,
Lamaziere JM, Bonnet J (1998) Vitronectin expression and
interaction with receptors in smooth muscle cells from human
atheromatous plaque. Arterioscler Thromb Vasc Biol 18(2):
168–176
60. Renault MA, Jalvy S, Belloc I, Pasquet S, Sena S, Olive M,
Desgranges C, Gadeau AP (2003) AP-1 is involved in UTP-
478 Purinergic Signalling (2006) 2:471–480induced osteopontin expression in arterial smooth muscle cells.
Circ Res 93(7):674–681
61. Renault MA, Jalvy S, Potier M, Belloc I, Genot E, Dekker LV,
Desgranges C, Gadeau AP (2005) UTP induces osteopontin
expression through a coordinate action of NFκB, activator
protein-1, and upstream stimulatory factor in arterial smooth
muscle cells. J Biol Chem 280(4):2708–2713
62. Communi D, Janssens R, Suarez-Huerta N, Robaye B,
Boeynaems JM (2000) Advances in signalling by extracellular
nucleotides. The role and transduction mechanisms of P2Y
receptors. Cell Signal 12(6):351–360
63. Parker AL, Likar LL, Dawicki DD, Rounds S (1996) Mechanism
of ATP-induced leukocyte adherence to cultured pulmonary
artery endothelial cells. Am J Physiol 270:L695–L703
64. Weisman GA, Yu N, Liao Z, Gonzalez F, Erb L, Seye CI (2005)
P2 Receptors in health and disease. Biotechnology and genetics.
22:171–195
65. Faruqi RM, DiCorleto PE (1993) Mechanisms of monocyte
recruitment and accumulation. Br Heart J 69:S19–S29
66. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis
V, Gutierrez-Ramos JC, Connelly PW, Milstone DS (2001) A
major role for VCAM-1, but not ICAM-1, in early atheroscle-
rosis. J Clin Invest 107(10):1255–1262
67. Rice GE, Munro JM, Bevilacqua MP (1990) Inducible cell
adhesion molecule 110 (INCAM-110) is an endothelial receptor
for lymphocytes. A CD11/CD18-independent adhesion mecha-
nism. J Exp Med 171(4):1369–1374
68. Iademarco MF, Barks JL, Dean DC (1995) Regulation of
vascular cell adhesion molecule-1 expression by IL-4 and
TNF-alpha in cultured endothelial cells. J Clin Invest 95
(1):264–271
69. Braun M, Pietsch P, Felix SB, Baumann G (1995) Modulation of
intercellular adhesion molecule-1 and vascular cell adhesion
molecule-1 on human coronary smooth muscle cells by
cytokines. J Mol Cell Cardiol 27(12):2571–2579
70. Ventura MA, Thomopoulos P (1995) ADP and ATP activate
distinct signaling pathways in human promonocytic U-937 cells
differentiated with 1,25-dihydroxy-vitamin D3. Mol Pharmacol
47(1):104–107
71. Seye CI, Yu N, Jain R, Kong Q, Minor T, Newton J, Erb L,
Gonzalez FA, Weisman GA (2003) The P2Y2 nucleotide
receptor mediates UTP-induced vascular cell adhesion mole-
cule-1 expression in coronary artery endothelial cells. J Biol
Chem 278(27):24960–24965
72. Liu J, Liao Z, Camden J, Griffin KD, Garrad RC, Santiago-Perez
LI, Gonzalez FA, Seye CI, Weisman GA, Erb L (2004) Src
homology 3 binding sites in the P2Y2 nucleotide receptor
interact with Src and regulate activities of Src, proline-rich
tyrosine kinase 2, and growth factor receptors. J Biol Chem 279
(9):8212–8218
73. Seye CI, Yu N, Gonzalez FA, Erb L, Weisman GA (2004) The
P2Y2 nucleotide receptor mediates vascular cell adhesion
molecule-1 expression through interaction with VEGF receptor-
2 (KDR/Flk-1). J Biol Chem 279(34):35679–35686
74. Mallat Z, Tedgui A (2000) Apoptosis in the vasculature:
mechanisms and functional importance. Br J Pharmacol 130
(5):947–962
75. Thomas WA, Reiner JM, Florentin FA, Lee KT, Lee WM (1976)
Population dynamics of arterial smooth muscle cells, V: cell
proliferation and cell death during initial 3 months in athero-
sclerotic lesions induced in swine by hypercholesterolemic diet
and intimal trauma. Exp Mol Pathol 24(3):360–374
76. Han DK, Haudenschild CC, Hong MK, Tinkle BT, Leon MB,
Liau G (1995) Evidence for apoptosis in human atherogenesis
and in a rat vascular injury model. Am J Pathol 147(2):
267–277
77. Geng YJ, Libby P (1995) Evidence for apoptosis in advanced
human atheroma: colocalization with interleukin-1β-converting
enzyme. Am J Pathol 147(2):251–266
78. Crisby M, Kallin B, Thyberg J, Zhivotovsky B, Orrenius S,
Kostulas V, Nilsson J (1997) Cell death in human atherosclerotic
plaques involves both oncosis and apoptosis. Atherosclerosis
130(1–2):17–27
79. Björkerud S, Björkerud B (1996) Apoptosis is abundant in
human atherosclerotic lesions, especially in inflammatory cells
(macrophages and T cells), and may contribute to the accumu-
lation of gruel and plaque instability. Am J Pathol 149(2):367–
380
80. Bochaton-Piallat ML, Gabbiani F, Redard M, Desmoulière A,
Gabbiani G (1995) Apoptosis participates in cellularity regula-
tion during rat aortic intimal thickening. Am J Pathol 146
(5):1059–1064
81. Burnstock G (1999) Release of vasoactive substances from
endothelial cells by shear stress and purinergic mechanosensory
transduction. J Anat 194:335–342
82. Kaiser D, Freyberg MA, Friedl P (1997) Lack of hemodynamic
forces triggers apoptosis in vascular endothelial cells. Biochem
Biophys Res Commun 231(3):586–590
83. Zheng LM, Zychlinsky A, Liu CC, Ojcius DM, Young JD
(1991) Extracellular ATP as a trigger for apoptosis or pro-
grammed cell death. J Cell Biol 112(2):279–288
84. Di Virgilio F, Zanovello P, Zambon A, Bronte V, Pizzo P, Murgia
M (1995) Cell membrane receptors for extracellular ATP: a new
family of apoptosis-signalling molecules. Fundam Clin Immunol
3:80–81
85. Jacobson KA, Hoffmann C, Cattabeni F, Abbracchio MP (1999)
Adenosine-induced cell death: evidence for receptor-mediated
signalling. Apoptosis 4(3):197–211
86. Wen LT, Caldwell CC, Knowles AF (2003) Poly (ADP-ribose)
polymerase activation and changes in Bax protein expression
associated with extracellular ATP-mediated apoptosis in human
embryonic kidney 293-P2X7 cells. Mol Pharmacol 63(3):
706–713
87. Wang Q, Wang L, Feng YH, Li X, Zeng R, Gorodeski GI (2004)
P2X7 receptor-mediated apoptosis of human cervical epithelial
cells. Am J Physiol Cell Physiol 287(5):C1349–C1358
88. Kong Q, Wang M, Liao Z, Camden JM, Yu S, Simonyi A, Sun
GY, Gonzalez FA, Erb L, Seye CI, Weisman GA (2005) P2X7
nucleotide receptors mediate caspase-8/9/3-dependent apoptosis
in rat primary cortical neurons. Purinergic Signalling 1(4):337–
347
89. Peyot M, Gadeau A, Dandré F, Belloc I, Dupuch F, Desgranges
C (2000) Extracellular adenosine induces apoptosis of human
arterial smooth muscle cells via A2b-receptor. Circ Res 86(1):
76–85
90. Solini A, Chiozzi P, Falzoni S, Morelli A, Fellin R, Di Virgilio
F (2000) High glucose modulates P2X7 receptor-mediated
function in human primary fibroblasts. Diabetologia 43(10):
1248–1256
91. Zanovello P, Bronte V, Rosato A, Pizzo P, and Di Virgilio F
(1990) Responses of mouse lymphocytes to extracellular ATP. II.
Extracellular ATP causes cell type-dependent lysis and DNA
fragmentation. J Immunol 145(5):1545–1550
92. Hogquist KA, Nett MA, Unanue ER, Chaplin DD (1991)
Interleukin 1 is processed and released during apoptosis. Proc
Natl Acad Sci USA 88(19):8485–8491
93. Lammas DA, Stober C, Harvey CJ, Kendrick N, Panchalingam
S, Kumararatne DS (1997) ATP-induced killing of mycobacteria
by human macrophages is mediated by purinergic P2Z (P2X7)
receptors. Immunity 7(3):433–444
94. Schulze-Lohoff E, Hugo C, Rost S, Arnold S, Gruber A, Brune
B, Sterzel RB (1998) Extracellular ATP causes apoptosis and
Purinergic Signalling (2006) 2:471–480 479necrosis of cultured mesangial cells via P2Z/P2X7 receptors. Am
J Physiol 275:F962–F971
95. Coutinho-Silva R, Persechini PM, Da Cunha Bisaggio R,
Perfettini J, Torres de Santo AC, Kanellopoulos JM, Mottaly I,
Dautry-Varsat A, Ojcius DM (1999) P2Z/P2X7 receptor-depen-
dent apoptosis of dendritic cells. Am J Physiol 276:C1139–
C1147
96. Ferrari D, Los M, Bauer MK, Vandenabeele P, Wesselborg S,
Schulze-Osthoff K (1999) P2Z purinoreceptor ligation induces
activation of caspases with distinct roles in apoptotic and
necrotic alterations of cell death. FEBS Lett 447(1):71–75
97. Ferrari D, Wesselborg S, Bauer MK, Schulze-Osthoff K (1997)
Extracellular ATP activates transcription factor NF-κB through
the P2Z purinoreceptor by selectively targeting NF-κB p65.
J Cell Biol 139(7):1635–1643
98. Hu Y, Fisette PL, Denlinger LC, Guadarrama AG, Sommer JA,
Proctor RA, Bertics PJ (1998) Purinergic receptor modulation of
lipopolysaccharide signaling and inducible nitric-oxide synthase
expression in RAW 264.7 macrophages. J Biol Chem 273
(42):27170–27175
99. Von Albertini M, Palmetshofer A, Kaczmarek E, Koziak K,
Stroka D, Grey ST, Stuhlmeier KM, Robson SC (1998)
Extracellular ATP and ADP activate transcription factor NF-κB
and induce endothelial cell apoptosis. Biochem Biophys Res
Commun 248(3):822–829
100. De Meyer GR, Van Put DJ, Kockx MM, Van Schil P, Bosmans
R, Bult H, Buyssens N, Vanmaele R, Herman AG (1997)
Possible mechanisms of collar-induced intimal thickening.
Arterioscler Thromb Vasc Biol 17(10):1924–1930
101. Wang L, Andersson M, Karlsson L, Watson MA, Cousens DJ,
Jern S, Erlinge D (2003) Increased mitogenic and decreased
contractile P2 receptors in smooth muscle cells by shear stress in
human vessels with intact endothelium. Arterioscler Thromb
Vasc Biol 23(8):1370–1376
102. Pulvirenti TJ, Yin JL, Chaufour X, McLachlan C, Hambly BD,
Bennett MR, Barden JA (2000) P2X (purinergic) receptor
redistribution in rabbit aorta following injury to endothelial cells
and cholesterol feeding. J Neurocytol 29(9):623–631
103. Katoh Y, Periasamy M (1996) Growth and differentiation of
smooth muscle cells during vascular development. Trends
Cardiovasc Med 6:100–106
104. Owens GK (1995) Regulation of differentiation of vascular
smooth muscle cells. Physiol Rev 75(3):487–517
105. Gabbiani G, Kocher O, Bloom WS, Vandekerckhove J, Weber K
(1984) Actin expression in smooth muscle cells of rat aortic
intimal thickening, human atheromatous plaque, and cultured rat
aortic media. J Clin Invest 73(1):148–152
106. Kocher O, Gabbiani F, Gabbiani G, Reidy MA, Cokay M,
Petters H, Huttner I (1991) Phenotypic features of smooth
muscle cells during the evolution of experimental carotid artery
intimal thickening: biochemical and morphologic studies. Lab
Invest 65(4):459–470
107. Schwartz SM, deBlois D, O’Brien ER (1995) The intima: soil for
atherosclerosis and restenosis. Circ Res 77(3):445–465
108. Ralevic V, Burnstock G (1991) Effects of purines and pyrimidines
on the rat mesenteric arterial bed. Circ Res 69(6):1583–1590
109. Saïag B, Milon D, Allain H, Rault B, Van Den Driessche J
(1990) Constriction of the smooth muscle of rat tail and femoral
arteries and dog saphenous vein is induced by uridine triphos-
phate via `pyrimidinoceptors’, and by adenosine triphosphate via
P2X receptors. Blood Vessels 27(6):352–354
110. Andersen HR, Mæng M, Thorwest M, Falk E (1996) Remodel-
ing rather than neointimal formation explains luminal narrowing
after deep vessel wall injury: insights from a porcine coronary
(re)stenosis model. Circulation 93(9):1716–1724
111. Clowes AW, Clowes MM, Reidy MA (1986) Kinetics of cellular
proliferationafterarterialinjury.III.Endothelialandsmoothmuscle
growth in chronically denuded vessels. Lab Invest 54(3):295–303
112. Haudenschild CC, Schwartz SM (1979) Endothelial regenera-
tion. II. Restitution of endothelial continuity. Lab Invest 41
(5):407–418
113. Shimokawa H, Flavahan NA, Vanhoutte PM (1989) Natural
course of the impairment of endothelium-dependent relaxations
after balloon endothelium removal in porcine coronary arteries:
possible dysfunction of a pertussis toxin-sensitive G protein. Circ
Res 65(3):740–753
114. Weidinger FF, McLenachan JM, Cybulsky MI, Gordon JB,
Rennke HG, Hollenberg NK, Fallon JT, Ganz P, Cooke JP (1990)
Persistent dysfunction of regenerated endothelium after balloon
angioplasty of rabbit iliac artery. Circulation 81(5):1667–1679
115. Valera S, Hussy N, Evans RJ, Adami N, North RA, Surprenant
A, Buell G (1994) A new class of ligand gated ion channel
defined by P2X receptor for extracellular ATP. Nature 371
(6497):516–519
116. Nicholas RA, Watt WC, Lazarowski ER, Li Q, Harden TK
(1996) Uridine nucleotide selectivity of three phospholipase
C-activating P2 receptors: identification of a UDP-selective, a
UTP-selective, and an ATP- and UTP-specific receptor. Mol
Pharmacol 50(2):224–229
117. Gordon JL (1986) Extracellular ATP: effects, sources and fate.
Biochem J 233(2):309–319
118. Bergfeld GR, Forrester T (1992) Release of ATP from human
erythrocytes in response to a brief period of hypoxia and
hypercapnia. Cardiovasc Res 26(1):40–47
119. Bodin P, Burnstock G (1995) Synergistic effect of acute hypoxia
on flow-induced release of ATP from cultured endothelial cells.
Experientia 51(3):256–259
120. Viswanathan M, Strömberg C, Seltzer A, Saavedra JM (1992)
Balloon angioplasty enhances the expression of angiotensin II
AT1 receptors in neointima of rat aorta. J Clin Invest 90
(5):1707–1712
121. Winkles JA, Alberts GF, Brogi E, Libby P (1993) Endothelin-1
and endothelin receptor mRNA expression in normal and
atherosclerotic human arteries. Biochem Biophys Res Commun
191(3):1081–1088
122. Majesky MW, Reidy MA, Bowen-Pope DF, Hart CE, Wilcox JN
(1990) PDGF ligand and receptor gene expression during repair
of arterial injury. J Cell Biol 111:2149–2158
480 Purinergic Signalling (2006) 2:471–480